MEGACE
LOE ApproachingNDAORALSUSPENSION
Approved
Sep 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
MEGACE by Bristol Myers Squibb is cachexia. Approved for anorexia, cachexia, an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). First approved in 1993.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEGACE is an oral suspension containing megestrol acetate approved in 1993 for treating anorexia, cachexia, and unexplained weight loss in AIDS patients. The precise mechanism of action remains unknown, though it is believed to work through appetite stimulation and metabolic modulation. It is a small-molecule oral formulation addressing a critical symptom management need in immunocompromised populations.
LOE Approaching
LOE-approaching product with minimal current commercial momentum; teams are likely in maintenance or transition phase with reduced headcount growth.
Worked on MEGACE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.